179 related articles for article (PubMed ID: 24867692)
1. Chemotherapy-induced dynamic gene expression changes in vivo are prognostic in ovarian cancer.
Koussounadis A; Langdon SP; Harrison DJ; Smith VA
Br J Cancer; 2014 Jun; 110(12):2975-84. PubMed ID: 24867692
[TBL] [Abstract][Full Text] [Related]
2. Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models.
Koussounadis A; Langdon SP; Um I; Kay C; Francis KE; Harrison DJ; Smith VA
BMC Cancer; 2016 Mar; 16():205. PubMed ID: 26964739
[TBL] [Abstract][Full Text] [Related]
3. An apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer.
Janzen DM; Tiourin E; Salehi JA; Paik DY; Lu J; Pellegrini M; Memarzadeh S
Nat Commun; 2015 Aug; 6():7956. PubMed ID: 26234182
[TBL] [Abstract][Full Text] [Related]
4. Imaging of treatment response to the combination of carboplatin and paclitaxel in human ovarian cancer xenograft tumors in mice using FDG and FLT PET.
Munk Jensen M; Erichsen KD; Björkling F; Madsen J; Jensen PB; Sehested M; Højgaard L; Kjær A
PLoS One; 2013; 8(12):e85126. PubMed ID: 24386456
[TBL] [Abstract][Full Text] [Related]
5. Sustained platelet-sparing effect of weekly low dose paclitaxel allows effective, tolerable delivery of extended dose dense weekly carboplatin in platinum resistant/refractory epithelial ovarian cancer.
Sharma R; Graham J; Blagden S; Gabra H
BMC Cancer; 2011 Jul; 11():289. PubMed ID: 21745358
[TBL] [Abstract][Full Text] [Related]
6. Promotive role of recombinant HE4 protein in proliferation and carboplatin resistance in ovarian cancer cells.
Wang H; Zhu L; Gao J; Hu Z; Lin B
Oncol Rep; 2015 Jan; 33(1):403-12. PubMed ID: 25354091
[TBL] [Abstract][Full Text] [Related]
7. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
8. Corilagin sensitizes epithelial ovarian cancer to chemotherapy by inhibiting Snail‑glycolysis pathways.
Jia L; Zhou J; Zhao H; Jin H; Lv M; Zhao N; Zheng Z; Lu Y; Ming Y; Yu Y
Oncol Rep; 2017 Oct; 38(4):2464-2470. PubMed ID: 28791374
[TBL] [Abstract][Full Text] [Related]
9. Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line.
Teng PN; Bateman NW; Wang G; Litzi T; Blanton BE; Hood BL; Conrads KA; Ao W; Oliver KE; Darcy KM; McGuire WP; Paz K; Sidransky D; Hamilton CA; Maxwell GL; Conrads TP
Hum Cell; 2017 Jul; 30(3):226-236. PubMed ID: 28251557
[TBL] [Abstract][Full Text] [Related]
10. Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: predicting platinum resistance.
Ferriss JS; Kim Y; Duska L; Birrer M; Levine DA; Moskaluk C; Theodorescu D; Lee JK
PLoS One; 2012; 7(2):e30550. PubMed ID: 22348014
[TBL] [Abstract][Full Text] [Related]
11. The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer.
Huang R; Langdon SP; Tse M; Mullen P; Um IH; Faratian D; Harrison DJ
Oncotarget; 2016 Jan; 7(4):4695-711. PubMed ID: 26683361
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of HECTD3 by HER2 inhibition makes serous ovarian cancer cells sensitive to platinum treatment.
Shu T; Li Y; Wu X; Li B; Liu Z
Cancer Lett; 2017 Dec; 411():65-73. PubMed ID: 28989055
[TBL] [Abstract][Full Text] [Related]
13. Expression of RET finger protein predicts chemoresistance in epithelial ovarian cancer.
Horio M; Kato T; Mii S; Enomoto A; Asai M; Asai N; Murakumo Y; Shibata K; Kikkawa F; Takahashi M
Cancer Med; 2012 Oct; 1(2):218-29. PubMed ID: 23342271
[TBL] [Abstract][Full Text] [Related]
14. HOTAIR promotes paclitaxel resistance by regulating CHEK1 in ovarian cancer.
Jiang J; Wang S; Wang Z; Cai J; Han L; Xie L; Han Q; Wang W; Zhang Y; He X; Yang C
Cancer Chemother Pharmacol; 2020 Aug; 86(2):295-305. PubMed ID: 32743678
[TBL] [Abstract][Full Text] [Related]
15. [Alteration of survivin gene expression in ovarian cancer cell line CAOV3 after chemotherapy in vitro].
Zhang SL; Jiang T; Lin B; Zhao CQ; Meng LR
Zhonghua Fu Chan Ke Za Zhi; 2004 Jul; 39(7):482-5. PubMed ID: 15347474
[TBL] [Abstract][Full Text] [Related]
16. A systematic overview of chemotherapy effects in ovarian cancer.
Högberg T; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
[TBL] [Abstract][Full Text] [Related]
17. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
[TBL] [Abstract][Full Text] [Related]
18. Carboplatin and taxol resistance develops more rapidly in functional BRCA1 compared to dysfunctional BRCA1 ovarian cancer cells.
Busschots S; O'Toole S; O'Leary JJ; Stordal B
Exp Cell Res; 2015 Aug; 336(1):1-14. PubMed ID: 25499884
[TBL] [Abstract][Full Text] [Related]
19. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
20. Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study.
Benson EA; Skaar TC; Liu Y; Nephew KP; Matei D
PLoS One; 2015; 10(10):e0141279. PubMed ID: 26485143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
